LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys.

Adams, Andrew C; Halstead, Carolyn A; Hansen, Barbara C; Irizarry, Armando R; Martin, Jennifer A; Myers, Sharon R; Reynolds, Vincent L; Smith, Holly W; Wroblewski, Victor J; Kharitonenkov, Alexei

Adams, Andrew C; Halstead, Carolyn A; Hansen, Barbara C; Irizarry, Armando R; Martin, Jennifer A; Myers, Sharon R; Reynolds, Vincent L; Smith, Holly W; Wroblewski, Victor J; Kharitonenkov, Alexei.

Affiliation

Adams AC; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.

PLoS One ; 8(6): e65763, 2013.

Article in En | MEDLINE | ID: mdl-23823755

Subject(s)

Diabetes Mellitus, Experimental/metabolism; Fibroblast Growth Factors/pharmacology; Adipokines/blood; Animals; Blood Glucose/analysis; Disease Progression; Dose-Response Relationship, Drug; Energy Intake/drug effects; Fibroblast Growth Factors/pharmacokinetics; Insulin/blood; Macaca mulatta; Weight Loss/drug effects

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Experimental / Fibroblast Growth Factors Limits: Animals Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2013 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google